Peter Thiel Made A Fortune On Palantir — Here Are His 3 Other Bets

Peter Thiel is a master at putting his money in the right place at the right time. But new S&P 500 member Palantir (PLTR) is just one of his big bets.

↑
X

NOW PLAYING
Beating The Market: How To Find Outperforming Stocks

The lawyer, PayPal (PYPL) co-founder and investor best known as being the first outsider to put money into Facebook, reports stakes in three other public companies in addition to Palantir, says an Investor’s Business Daily analysis of data from S&P Global Market Intelligence and MarketSurge.

Those are communications firm PropertyGuru Group (PGRU) and health care plays AbCellera Biologics (ABCL) and Chemomab Therapeutics (CMMB).

These plays are part of Thiel’s hot hand. But Palantir, a government technology contractor, is the latest home run for Thiel after its inclusion last week in the S&P 500. The stock is up 102% just this year.

“Unlike an appointment to the Dow, being added to the S&P 500 can generate a sustainable increase in a stock’s price performance. PLTR has proved the naysayers wrong since the beginning of the year,” said Nancy Tengler of Laffer Tengler Investments.

Thiel’s Palantir Score

Talk about a solid investment. Thiel’s 223.6 million shares in the technology company are now valued at roughly $7.7 billion. He owns nearly 10% of the company — making him the largest owner of the stock — ahead of even indexing giants Vanguard and BlackRock.

And there’s plenty of fundamental strength to back up Palantir’s technicals. Analysts think profit will rise 42% this year and 18% in 2025. The stock sports a Composite Rating of 99 and EPS Rating of 96.

But what about Thiel’s other public bets?

Looking At Thiel’s Portfolio

PropertyGuru Group is another of Thiel’s fliers. He owns 3.7 million shares of the digital rental marketplace, making him a top 10 owner.

So far, the stock is working well. Shares are up nearly 100% just this year. That brings the value of his stake to roughly $24 million. Again, analysts see huge growth. The company’s bottom line is seen rising 28% this year and 61% in 2025. It already has a 76 Composite Rating. Thiel isn’t alone in appreciating this company. It’s set to be bought by EQT Private Capital Asia for $1.1 billion.

Not all of Thiel’s moves, though, work out all the time. He also owns a roughly $24 million stake in AbCellera Biologics. It’s a development stage company working on antibody based treatments. Shares are down 55% this year.

But if Palantir shows anything, it’s that you should think twice before betting against Thiel.

Peter Thiel’s Top Public Holdings

Sources: IBD, S&P Global Market Intelligence